PARP Inhibitors: Current and Future

Speaker: Thomas Halleday

Prof. Thomas Helleday’s translational research work is mainly focused on understanding basic DNA repair and DNA-damage signalling pathways. We met him at the ESMO Symposium on Signalling Pathways in Cancer 2017, where he spoke about the current status of PARP inhibitors and what we can expect in the future.

Discussion Points


  • Characteristics of PARP inhibitors as a class of agents
  • Current approvals for clinical use
  • Future outlook